Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Drug Profile

Research programme: ischaemia reperfusion injury therapeutics - DecImmune Therapeutics

Alternative Names: Anti-N2 monoclonal antibody - DecImmune Therapeutics; Anti-N2F(ab')2 MAb; Antibody 21G6 - DecImmune Therapeutics; DeciMab; N2 inhibitors - DecImmune Therapeutics; Non-muscle myosin heavy-chain II inhibitors - DecImmune Therapeutics; Synthetic N2 peptide - DecImmune Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DecImmune Therapeutics
  • Class Antibodies; Monoclonal antibodies; Peptides
  • Mechanism of Action Inflammation mediator inhibitors; Myosin type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myocardial ischaemia; Reperfusion injury

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Myocardial-ischaemia in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Reperfusion-injury in USA
  • 03 Oct 2014 DecImmune receives SBIR phase IIb grant from the US National Institutes of Health for development of its N2-targeted monoclonal therapeutic in vascular inflammatory diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top